BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial



    Toronto Stock Exchange Symbol: MS

    EDMONTON, Aug. 1 /CNW/ - BioMS Medical Corp. (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that it
has completed patient recruitment in its phase III clinical trial of MBP8298
(dirucotide) for the treatment of secondary progressive MS (SPMS). The trial,
named MAESTRO-03, includes approximately 510 patients, and is being conducted
at 68 trial sites in the U.S.
    "We have had great success in recruiting patients into the trial, which
is a testament to the promise of our approach and the efforts of our
investigators," said Mr. Kevin Giese, President and CEO. "Since initiating
this trial in June 2007 we have been delighted by the enthusiasm of the
patients and clinical groups participating across the U.S."

    
    MBP8298 (dirucotide) is currently being developed in three late-stage
clinical trials:

    1. MAESTRO-01: A pivotal phase II/III trial for secondary progressive MS
       (SPMS) patients in Canada and Europe.
    2. MAESTRO-03: A pivotal phase III trial for SPMS patients in the United
       States.
    3. MINDSET-01: A phase II trial for relapsing-remitting MS (RRMS)
       patients in Europe.
    

    About MAESTRO-03
    ----------------
    The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized,
double-blind study that has completed recruitment of approximately 510
patients at 68 clinical sites who will be administered either MBP8298
(dirucotide) or placebo intravenously every six months for a period of two
years. The primary clinical endpoint for the trial is defined as a
statistically and clinically significant increase in the time to progression
of the disease as measured by the Expanded Disability Status Scale (EDSS), in
patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all
MS patients are HLA-DR2 and/or HLA-DR4 positive).

    About MBP8298 (dirucotide)
    --------------------------
    MBP8298 (dirucotide) is a synthetic peptide that consists of 17 amino
acids having a sequence identical to that of a portion of human myelin basic
protein (MBP). MBP8298 (dirucotide) is being developed for the potential
treatment of multiple sclerosis (MS), an autoimmune disease caused by immune
attack against normal components of the central nervous system. The sequence
of MBP8298 is associated with the autoimmune process in MS patients with
certain immune response genes (HLA types DR2 and/or DR4); MS patients having
these genes represent 65 to 75 percent of all MS patients.
    The apparent mechanism of action of MBP8298 (dirucotide) is the induction
or restoration of immunological tolerance with respect to ongoing immune
attack as a result of high doses of peptide delivered periodically by the
intravenous route. The potential benefit of MBP8298 (dirucotide) for any
individual patient is therefore expected to be related to the role this
peptide plays in that patient's immune system. The degree of immunomodulation
achieved will depend on the relationship among the peptide, HLA molecules and
T cells.
    The results of phase II and long-term follow-up treatment of MS patients
with MBP8298 (dirucotide), published in 2006 in the European Journal of
Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time
to disease progression for five years (versus placebo) in progressive MS
patients with HLA types DR2 and/or DR4. Thus, MBP8298 (dirucotide) has the
potential to be used as a tailored therapy for patients genetically determined
to express the appropriate HLA molecules.

    About Multiple Sclerosis
    ------------------------
    Multiple sclerosis (MS) is thought to affect as many as 2.5 million
people worldwide, including approximately 75,000 in Canada, 400,000 in the
United States and more than 500,000 in Europe. It is a disease that affects
more women than men, with onset typically occurring between 20 and 50 years of
age. MS is caused by damage to myelin, the protective sheath surrounding nerve
fibers in the central nervous system, which interferes with messages from the
brain to the body. Symptoms of MS may include vision problems, loss of
balance, numbness, difficulty walking and paralysis. Approximately 40 percent
of all MS patients have the secondary progressive form of the disease.

    About BioMS Medical Corp.
    -------------------------
    BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, MBP8298 (dirucotide), is for the treatment of multiple sclerosis
and is being evaluated in two pivotal phase III clinical trials for secondary
progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the
United States. It additionally is being evaluated for relapsing remitting MS
patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007,
BioMS entered into a licensing and development agreement granting Eli Lilly
and Company exclusive worldwide rights to MBP8298 (dirucotide) in exchange for
an $87 million upfront payment, milestone payments and escalating royalties on
sales. For further information please visit our website at
www.biomsmedical.com.

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that MBP8298 will continue to demonstrate a satisfactory safety
profile in ongoing and future clinical trials; and that BioMS Medical Corp.
will complete the respective clinical trials within the timelines communicated
in this release. We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.





For further information:

For further information: Tony Hesby, Ryan Giese, Corporate
Communications, BioMS Medical Corp., (780) 413-7152, (780) 408-3040 Fax,
E-mail: rgiese@biomsmedical.com, Internet: www.biomsmedical.com; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail:
jsmith@equicomgroup.com

Organization Profile

Medwell Capital Corp.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890